2b乔巴发琴无力罗宾彩色_日韩欧美理论一级片_日韩欧美中文字幕在_韩国三级在线不卡播放_美女靠逼软件_99无码蜜臀人妻久久精品_九九精品亚洲视频_国产大学生闺蜜AV在线播放_主人给我戴上奶牛榨乳器调教_被灌满精子的波多野结衣

On the morning of December 14, 2020, Kexing Biopharm (stock code: 688136) was officially listed on the Sci-Tech Innovation Board. The listing ceremony was held in the Shanghai Stock Exchange, and attended by the following: Bian Xiangwei, Deputy Secretary and Director of Zhangqiu District Committee of Jinan City; Huang Bo, Deputy Secretary of Party Working Committee and Director of Management Committee of Mingshui Economic and Technological Development Zone; representatives of intermediary agencies, clients, suppliers, shareholders and employee representatives.

Deng Xueqin, chairman of Kexing Biopharm, said at the listing ceremony that the successful listing was an important strategic measure for Kexing Biopharm to become a "leader in the industry of high-quality biopharmaceuticals" and was a major milestone in the company history. The state places great hopes on scientific innovation. Kexing Biopharm will select development platforms and seize the opportunities brought by this listing, make full use of capital force, further improve its innovation ability, and provide patients with biotechnologies. It is committed to becoming a leading innovative biopharmaceutical enterprise in China. It will return the trust and support of the majority of investors and all sectors of society with excellent performance, and make contributions to the high-quality development of the Chinese pharmaceutical industry!

Address by Deng Xueqin, Chairman of Kexing Biopharm

China Securities Co., Ltd. was the sponsor and lead underwriter for the listing of Kexing Biopharm. Liu Naisheng, a member of the Executive Committee of China Securities, gave his warmest congratulations as a representative. He said that Kexing Biopharm was one of the first domestic practitioners in biomedical innovation and pioneers in commercial production, who witnessed the birth, development and growth of biomedicine in China. Kexing Biopharm's Recombinant Human Interferon is a broad-spectrum antiviral drug and has been used to fight against SARS and COVID-19 as a core product, playing a role in epidemic prevention and control and following the original aspiration of pharmaceuticals. In the new development stage, Kexing Biopharm has got access to the capital market. Adhering to the mission of "Precise Products, Predictable Effects and Health Protection", it stayed focus on biopharmaceuticals. With the help of capital force, it will certainly grow into one of the core forces of biomedical innovation in China.

Address by Liu Naisheng, A Member of Executive Committee of China Securities

Bian Xiangwei, Deputy Secretary and Director of Zhangqiu District Committee of Jinan City expressed warm congratulations to Kexing Biopharm on behalf of Zhangqiu District Committee and Government. He said that the successful listing of Kexing Biopharm set an example for enterprises in the district and enhanced their confidence. With the great support of the capital market, Kexing Biopharm will be able to maintain a momentum of rapid growth, becoming a leading enterprise in the pharmaceutical industry.

Address by Bian Xiangwei, Deputy Secretary and Director of Zhangqiu District Committee of Jinan City

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of therapeutic recombinant proteins, modified proteins, fusion proteins and micro-ecological drug products. It focuses on pharmaceutical research in the fields of antiviral, oncology and immunology, hematology, and digestive system. The products on sale include "Recombinant Human Erythropoietin" (EPOSINO), "Recombinant Human Interferon α1b" (SINOGEN), "Recombinant Human Granulocyte Colony-stimulating Factor" (WHITE-C), and "Combined Clostridium Butyricum and Bifidobacterium" （CLOBICO）.

From 2017 to 2019, Kexing Biopharm achieved a revenue of RMB 616 million, RMB 891 million and RMB 1191 million, respectively, and a net profit attributable to shareholders of RMB 59,391,600, RMB 94,163,700 and RMB 159,810,400, respectively. From 2017 to 2019, Kexing Biopharm reached a compound revenue growth rate of 39.05%, and also achieved a substantial rise in net profit.

As a biopharmaceutical enterprise mainly engaged in the production of biopharmaceuticals with pure quality, Kexing Biopharm earned revenues mainly from Recombinant Human Erythropoietin and Recombinant Human Interferon α1b, RMB 559 million and RMB 353 million in 2019, respectively, accounting for 46.99% and 29.65% of gross revenue, respectively.

According to the statistical data of MENET, Kexing Biopharm's Recombinant Human Interferon α1b realized a market share of 21.45%, 23.95% and 26.29% in 2017, 2018 and 2019, respectively, ranking second in the domestic market of short-acting recombinant human interferon for injection.

Recombinant Human Erythropoietin (EPOSINO) achieved a market share of 9.36%, 11.27% and 12.51% in 2017, 2018 and 2019, respectively, ranking third in the domestic market. In addition, EPOSINO was obviously superior to other domestic products of the same type in terms of export business and has been approved for access to and sales in more than 20 countries.

With over two decades of experience in pharmaceutical research and commercial production technology since the establishment, Kexing Biopharm has had 3 major technology systems (prokaryotic cell technology, eukaryotic cell technology and viable micro-ecological bacteria technology), and has set up 5 world-leading platforms for strain technology, recombinant protein pharmaceutical industrialization technology, micro-ecological drug product R&D and industrialization technology, recombinant protein secretion and expression technology, and long-acting recombinant protein technology). Kexing Biopharm has obtained 36 patents, with 8 biopharmaceutical projects under research, including 2 projects of Class I innovative drugs.

Following the mission of "Precise Products, Predictable Effects and Health Protection", Kexing Biopharm is devoted to providing patients with biotechnologies, becoming a leading innovative biopharmaceutical enterprise in China.